Tags

Type your tag names separated by a space and hit enter

[Homocysteine and cognitive impairment in Parkinson's disease].
Rev Neurol. 2010 Feb 1-15; 50(3):145-51.RN

Abstract

INTRODUCTION

The relationship between homocysteine (Hc) and vascular diseases has been known for more than 30 years. Lately, Hc has also been related to cognitive and motor impairment. In Parkinson's disease (PD), chronic treatment with levodopa could induce higher levels of Hc, and thus may increase risk of cognitive impairment.

AIMS

To confirm that PD patients treated with levodopa have higher levels of Hc and to establish a relationship between Hc, folic acid and vitamin B12 levels. Also, we studied a possible link between those variables and cognitive function.

PATIENTS AND METHODS

58 patients with diagnosis of PD were included (45 under treatment with levodopa). Basal levels of Hc, vitamin B12 and folic acid were determined. Forty five patients underwent neuropsychological evaluation.

RESULTS

Hc levels were significantly higher in patients taking levodopa and were not related to levodopa dosage or treatment duration. There was a negative correlation between Hc levels and those of vitamin B12 and folic acid in men but we found no such correlation in women. Entacapone was not found to reduce Hc levels. Hc levels were significantly higher in patients with cognitive impairment (9 out of 45 patients).

CONCLUSIONS

Our study confirms presence of high levels of Hc in PD patients under treatment with levodopa, more evident in patients with cognitive impairment.

Authors+Show Affiliations

Servicio de Neurología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Espana. josej.martin@carm.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

20146187

Citation

Martín-Fernández, José Javier, et al. "[Homocysteine and Cognitive Impairment in Parkinson's Disease]." Revista De Neurologia, vol. 50, no. 3, 2010, pp. 145-51.
Martín-Fernández JJ, Carles-Díes R, Cañizares F, et al. [Homocysteine and cognitive impairment in Parkinson's disease]. Rev Neurol. 2010;50(3):145-51.
Martín-Fernández, J. J., Carles-Díes, R., Cañizares, F., Parra, S., Avilés, F., Villegas, I., Morsi-Hassan, O., Fernández-Barreiro, A., & Herrero, M. T. (2010). [Homocysteine and cognitive impairment in Parkinson's disease]. Revista De Neurologia, 50(3), 145-51.
Martín-Fernández JJ, et al. [Homocysteine and Cognitive Impairment in Parkinson's Disease]. Rev Neurol. 2010 Feb 1-15;50(3):145-51. PubMed PMID: 20146187.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Homocysteine and cognitive impairment in Parkinson's disease]. AU - Martín-Fernández,José Javier, AU - Carles-Díes,Rafael, AU - Cañizares,Francisco, AU - Parra,Soledad, AU - Avilés,Francisco, AU - Villegas,Irene, AU - Morsi-Hassan,Ossama, AU - Fernández-Barreiro,Andrés, AU - Herrero,M Trinidad, PY - 2010/2/11/entrez PY - 2010/2/11/pubmed PY - 2010/4/27/medline SP - 145 EP - 51 JF - Revista de neurologia JO - Rev Neurol VL - 50 IS - 3 N2 - INTRODUCTION: The relationship between homocysteine (Hc) and vascular diseases has been known for more than 30 years. Lately, Hc has also been related to cognitive and motor impairment. In Parkinson's disease (PD), chronic treatment with levodopa could induce higher levels of Hc, and thus may increase risk of cognitive impairment. AIMS: To confirm that PD patients treated with levodopa have higher levels of Hc and to establish a relationship between Hc, folic acid and vitamin B12 levels. Also, we studied a possible link between those variables and cognitive function. PATIENTS AND METHODS: 58 patients with diagnosis of PD were included (45 under treatment with levodopa). Basal levels of Hc, vitamin B12 and folic acid were determined. Forty five patients underwent neuropsychological evaluation. RESULTS: Hc levels were significantly higher in patients taking levodopa and were not related to levodopa dosage or treatment duration. There was a negative correlation between Hc levels and those of vitamin B12 and folic acid in men but we found no such correlation in women. Entacapone was not found to reduce Hc levels. Hc levels were significantly higher in patients with cognitive impairment (9 out of 45 patients). CONCLUSIONS: Our study confirms presence of high levels of Hc in PD patients under treatment with levodopa, more evident in patients with cognitive impairment. SN - 1576-6578 UR - https://www.unboundmedicine.com/medline/citation/20146187/[Homocysteine_and_cognitive_impairment_in_Parkinson's_disease]_ L2 - http://www.revneurol.com/LinkOut/formMedLine.asp?Refer=2009276&Revista=RevNeurol DB - PRIME DP - Unbound Medicine ER -